MDA-ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY
The DOI matches its Crossref record.
Abstract
Ten neurotic patients (five males and five females) were treated over a period of 2 to 6 months (mean, 4.1) as outpatients. The study allowed for a maximum of 75 hours of psychotherapy (mean, 51.55 hours). During the course of treatment, two to four (mean, 3.5) administrations of MDA (3,4-methylenedioxyamphetamine) were employed as adjunctive aids in an effort to enhance the psychotherapeutic process. The mean duration of the drug sessions was 8 hours (range, 6 to 14 hours). The first administration of MDA took place when, in the therapist's judgment, sufficient rapport had been established with the patient. All patients received an initial dose of 75 mg of MDA; subsequent dosage was allowed to range up to 200 mg. On these occasions, the drug appeared to be well tolerated with no serious side effects or complications observed. Psychometric assessments were obtained pre- and post-treatment, employing the Minnesota Multiphasic Personality Inventory (MMPI), Wittenborn Psychiatric Rating Scales (WPRS), and Brief Psychiatric Rating Scale (BPRS). In addition, follow-up evaluations were obtained 6 months after the termination of therapy by the use of the MMPI, WPRS, BPRS, and a Social History Questionnaire (SHQ) which had also been administered before treatment was initiated. Clinically, the impression was obtained that psychotherapy and the adjunctive use of MDA appeared to facilitate improvement in these patients. This impression was substantiated by significant reductions in scores on the psychometric assessments measuring depression, anxiety, and obsessive-compulsive traits. The meaures evaluating the sense of well-being and self-actualization also were encouraging. Although some of the patients were not as responsive as others, there were no observations to suggest that the condition of any of these patients had become worse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals
Ricaurte, G., Bryan, G., Strauss, L., Seiden, L., & Schuster, C. (1985) · Science · doi:10.1126/science.4023719 · Cited by 367
Johnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90615-1 · Cited by 306
Psychedelic medicine: a re-emerging therapeutic paradigm
Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015) · Canadian Medical Association Journal · doi:10.1503/cmaj.141124 · Cited by 187
Self-citationThe early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116
Metadata
- Authors
- YENSEN, R., DI LEO, F. B., RHEAD, J. C., RICHARDS, W. A., SOSKIN, R. A., TUREK, B., & KURLAND, A. A.
- Venue
- The Journal of Nervous and Mental Disease
- Published
- 1976-10
- Volume
- 163
- Issue
- 4
- Pages
- 233-245
- ISSN
- 0022-3018 (ISSN-L)
- OpenAlex
- W1978344327
- Cited by
- 53
- References
- 0
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDA-ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY. https://app.cochat.ai/papers/10.1097/00005053-197610000-00002
- The paper
- YENSEN, R., DI LEO, F. B., RHEAD, J. C., RICHARDS, W. A., SOSKIN, R. A., TUREK, B., & KURLAND, A. A. (1976). MDA-ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-197610000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.